Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 14 October 2022

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods in Australia, aiming to ensure that these goods are safe, of high quality, and perform as claimed. This Act was introduced to address the need for a comprehensive regulatory framework governing the manufacturing, supply, and advertising of therapeutic goods, which include medicines, medical devices, blood, and tissues. The enactment of this Act by the Commonwealth Parliament was driven by the policy objective of protecting public health and safety by ensuring that only those goods meeting specified standards are made available in the market. The Therapeutic Goods Administration, a part of the Department of Health and Aged Care, is responsible for the administration and enforcement of this Act. This legislative framework is crucial for maintaining public confidence in the therapeutic goods available in Australia, thereby facilitating access to safe and effective health products and services.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities engaged in the manufacturing, supply, and importation of therapeutic goods within Australia, encompassing a broad range of products such as medicines, medical devices, blood, and tissues. This Act regulates these activities to ensure the safety, quality, and efficacy of therapeutic goods, thereby protecting public health. The Act applies to manufacturers, importers, and suppliers who must obtain a licence to operate within the scope of the Act. The licences granted under the Act serve to confirm that the entities meet the required standards and regulations. The geographic scope of the Act is national, applying across all states and territories within Australia. There are no stated exclusions or exemptions in the Act itself; however, certain classes of goods such as food and cosmetics may be subject to other legislation. The application and enforcement of the Act can be extended or restricted through subordinate instruments, such as regulations and guidelines, which provide further detail on compliance and enforcement mechanisms.

Key Provisions

Section 38 of the Therapeutic Goods Act 1989 requires the Secretary to grant licences to entities that meet certain standards for the manufacture of therapeutic goods. The Act outlines that such licences are granted to manufacturers who can demonstrate compliance with the necessary quality, safety, and efficacy standards. This section specifically pertains to Syntro Pty Ltd, NaturaTech Pty Ltd, Complementary Medicines Group Pty Ltd, and Australian Red Cross Lifeblood, all of which have been issued licences to manufacture therapeutic goods, as evidenced by the publication dated 14 October 2022. Each licensee is identified by their respective licence number and address, ensuring transparency and accountability in the manufacturing process. The Act imposes several obligations on the licence holders, including the requirement to maintain high standards of quality control and assurance throughout the manufacturing process. These entities must adhere to Good Manufacturing Practice (GMP) standards, ensuring that their products are safe for use and meet the therapeutic needs they are intended to address. Additionally, the licence holders must keep accurate records of their manufacturing processes, ingredients, and quality control measures, which must be made available for inspection by the Therapeutic Goods Administration (TGA) upon request. This ensures ongoing compliance with regulatory standards and provides a safeguard for public health. Failure to comply with the requirements of the Therapeutic Goods Act 1989 can result in severe consequences. Section 41A of the Act outlines various offences related to the manufacture of therapeutic goods, including the unauthorised manufacture of a therapeutic good or the manufacture of a therapeutic good that does not comply with the Act. Penalties for breaches can include substantial fines and imprisonment. For example, individuals found guilty of manufacturing a therapeutic good without a valid licence may face fines of up to $1.1 million or imprisonment for up to 10 years, or both. Additionally, entities found in breach of the Act may also face civil penalties, including the suspension or revocation of their licence to manufacture therapeutic goods. These stringent measures are in place to ensure the highest standards of safety and quality in the therapeutic goods market.